Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Envafolimab (Primary)
  • Indications Biliary cancer; Bladder cancer; Breast cancer; Cervical cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Head and neck cancer; Liver cancer; Malignant melanoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors 3D Medicines

    • Most Recent Events

    • 01 Sep 2021 Results published in the Oncologist
    • 21 Mar 2021 Status changed from active, no longer recruiting to completed.
    • 02 Nov 2020 Planned End Date changed from 1 Aug 2021 to 1 Jan 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top